Health Policy
WHO guidelines, EU directives, and Georgian health governance
Biotech Industry Faces Political Uncertainty and AI Profitability Questions at BIO 2026
Biotech executives at BIO 2026 confronted mounting concerns over Chinese competition, the uncertain profitability of AI-driven drug discovery, and political…
Editor's Top Picks
Eli Lilly’s Obesity Drug Access: What We Know About FDA Approval Pathways
Regulatory pathways and corporate strategy shape early access to obesity drug candidates. Pharmaceutical acquisitions in the metabolic disease sector reflect…
Submit Your Paper →
More form Health Policy
Forty-eight years of WHO essential medicines: core drugs unchanged since 1977
A 48-year analysis of WHO's Essential Medicines List reveals a stable "core subset" of medications…
Mobile Phone Surveys Show Promise as Supplement to Traditional Mortality Surveillance in Bangladesh
Research published in Tropical Medicine & International Health shows mobile phone surveys could supplement traditional…
Why Food Labels Alone Won’t Stop Child Obesity in Latin America—Evidence From Ecuador
Latin American countries have implemented front-of-package warning labels and advertising restrictions, yet childhood obesity continues…
Why Adolescent Obesity Is Rising in the Digital Age—and How Digital Tools Can Help
Global adolescent obesity is rising due to digital food marketing and structural inequities. While digital…
Cancer Burden from Preventable Risk Factors Quantified in Landmark Global Study
A global analysis in Nature Medicine quantifies cancer burden from preventable risk factors across regions,…